Skip to main content
. 2021 Dec 17;10(24):5932. doi: 10.3390/jcm10245932

Table 2.

Patient group.

Disease Duration (years) 10.18 ± 5.53 (1–22)
EDSS 2.09 (1–7)
Disease-Modifying Treatment
  • -
    Interferon beta 1-a
    • Rebif
    • Avonex
  • -

    Teriflunomide

  • -

    Natalizumab

  • -

    Glatiramer acetate

  • -

    Interferon-beta 1-b

  • -

    Dimethyl fumarate
22 (36.06%)
12 (19.67%)
10 (16.39%)
15 (24.59%)
12 (19.67%)
8 (13.11%)
3 (4.91%)
1 (1.63%)